Orchid Pharma Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹5,352 Cr
- P/E
- 296.33
- ROE
- 1.49%
- PEG
- 5.62
- Price to sales
- 4.98
- Debt to equity
- 0.20
- 52W high / low
- ₹1,107 / ₹482
- Sales growth (5Y)
- 22.33%
- EBITDA margin
- 4.12%
- Net profit margin
- 1.83%
- Promoter holding
- 74.45%
- Sales (last year)
- ₹1,073 Cr
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
Guidance scorecard · Q1 FY27 call
What Orchid Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement.
- Management expects better Q-o-Q growth in H2 FY27, as regulated market demand typically picks up in the winter season.
- Volumes for key products like Exblifep in Europe exhibited significant sequential growth (300% in Q3 FY26, 170% in Q4 FY26, and 50% in Q1 FY27).
- The 7-ACA Jammu facility aims for commercial batch by March 2027 with ramp-up to 80-100% utilization by year-end.
- Long-term revenue from new products like Enmetazobactam has $1-2 billion lifetime sales potential.
- NP-NC segment sales were INR 21 crores in the recent quarter with ongoing incremental product additions.
2 more points from Orchid Pharma Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Orchid Pharma Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- FY27 capex is not expected to be very significant as major projects are nearing completion.
- INR 750 crores capex for the 7-ACA project.
- USD 20-25 million capex for the cefiderocol project.
- Current financial year will see completion of cefiderocol and 7-ACA projects.
- Strategic focus on backward integration into 7-ACA and cefiderocol access project to create diversified value.
2 more points from Orchid Pharma Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Orchid Pharma Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Orchid Pharma Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Orchid Pharma Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Orchid Pharma Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Orchid Pharma Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 74.45% |
| FIIs + | 4.14% | 1.96% | 1.42% | 1.94% | 2.53% | 2.69% | 1.39% | 1.56% | 1.17% | 0.87% | 0.80% | 0.93% |
| DIIs + | 14.51% | 17.73% | 18.93% | 18.30% | 19.00% | 20.10% | 19.43% | 19.04% | 19.38% | 20.24% | 20.75% | 17.44% |
| Public + | 11.52% | 10.47% | 9.82% | 9.94% | 8.63% | 7.37% | 9.34% | 9.57% | 9.61% | 9.04% | 8.62% | 7.17% |
| No. of Shareholders | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 | 33,433 | 33,790 |
Financials of Orchid Pharma Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 182.92 | 198.76 | 220.59 | 217.10 | 244.41 | 222.70 | 217.34 | 237.48 | 263.19 | 193.52 | 207.27 | 368.33 | 304.17 |
| Expenses + | 160.78 | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 268.84 | 194.99 | 205.71 | 338.17 | 290.17 |
| Operating Profit | 22.14 | 23.30 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14.00 |
| OPM % | 12.10% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% |
| Other Income + | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.90 | 11.57 | 10.77 | -1.50 | 7.55 | 1.83 |
| Interest | 5.55 | 3.80 | 3.54 | 3.47 | 3.50 | 3.33 | 3.80 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.90 | 9.03 | 10.90 | 10.95 |
| Profit before tax | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.90 | 22.45 | 19.10 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0.00% | 0.00% | 0.00% | -10.27% | -0.53% | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% |
| Net Profit + | 9.40 | 19.80 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS in Rs | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
Financials of Orchid Pharma Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Expenses + | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 1,247 | 1,185 | 1,029 |
| Operating Profit | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 18% | 20% | 0.4% | 3.6% | -2.0% | -6% | 7% | 10% | 13% | 14% | 11% | 3.9% | 4.1% |
| Other Income + | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 26 | 15 | 19 |
| Interest | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 13 | 9 | 11 |
| Depreciation | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 42 | 43 | 40 |
| Profit before tax | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 122 | 10 | 12 |
| Tax % | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -8% | -2% | |
| Net Profit + | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS in Rs | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 26.63 | 1.96 | 2.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Orchid Pharma Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 15 | 15 |
| Reserves | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,494 | 1,504 |
| Borrowings + | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 154 | 307 |
| Other Liabilities + | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 414 | 432 |
| Total Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
| Fixed Assets + | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 708 | 692 |
| CWIP | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 414 |
| Investments | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 60 | 67 |
| Other Assets + | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 1,229 | 1,086 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
Financials of Orchid Pharma Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 51 | 126 |
| Cash from Investing Activity + | 1,334 | -1 | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -36 | -277 |
| Cash from Financing Activity + | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 2 | 137 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 17 | -14 |
| Free Cash Flow | 965 | 211 | 392 | 3 | 5 | 77 | 23 | 238 | -8 | 61 | -102 | -255 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -102% | 124% | 13,628% | 67% | -138% | -226% | 63% | 173% | 22% | 113% | 44% | 259% |
Financials of Orchid Pharma Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 92 | 113 |
| Inventory Days | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 187 | 161 |
| Days Payable | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 137 | 150 |
| Cash Conversion Cycle | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 142 | 124 |
| Working Capital Days | -49 | -168 | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 101 | 105 |
| ROCE % | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 9% | 2% |
Guidance history
How Orchid Pharma Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Up 0–2% | Planned | — | — |
| Q3 FY26 call → | 0–10% | Up 0–2% | Planned | Planned | — |
| Q2 FY26 call → | Decline | Down 0–2% | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
36 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +25.1% | 76% |
| Last 6 months | +42.8% | 87% |
| Last 3 months | −10.7% | 38% |
The price is 65.5% below its all-time high of ₹2,588.4 (1 Apr 2021). Stocks more than 20% below their peak have their score halved, so 73 became 36.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Orchid Pharma Ltd: 0.4 × 76 + 0.4 × 87 + 0.2 × 38 = 73, halved to 36 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Orchid Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY